NCT01225393View on ClinicalTrials.gov

A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in Combination With a DMARD in Patients With Active Rheumatoid Arthritis

PHASE2CompletedINTERVENTIONAL
Enrollment

211

Participants

Timeline

Start Date

November 30, 2010

Primary Completion Date

July 31, 2012

Conditions
Rheumatoid Arthritis
Interventions
DRUG

MLTA3698A

Subcutaneous repeating dose

DRUG

adalimumab

Subcutaneous repeating dose

DRUG

leflunomide

Stable dose if not on methotrexate

DRUG

methotrexate

Stable dose if not on leflunomide

DRUG

placebo

Subcutaneous repeating dose

Trial Locations (67)

41

Lima

1027

Budapest

1036

Budapest

1233

Sofia

1407

Sofia

1505

Sofia

4032

Debrecen

5600

Békéscsaba

14059

Berlin

15006

A Coruña

21100

Mexicali

23320

Chesapeake

24105

Kiel

26301

Clarksburg

29406

Charleston

32174

Ormond Beach

35216

Birmingham

36207

Anniston

37320

León

38320

S. Cristobal de La Laguna

39232

Flowood

39261

Zerbst

39300

Torrelavega

40515

Lexington

41071

Seville

44340

Guadalajara

44600

Guadalajara

44620

México

44649

Herne

44690

Guadalajara

49009

Kalamazoo

50924

Cologne

61231

Bad Nauheim

64000

Monterrey, NL

78217

San Antonio

79106

Freiburg im Breisgau

80000

Culiacán

85381

Peoria

89502

Reno

90033

Los Angeles

91786

Upland

97000

Mérida

99096

Erfurt

400006

Cluj-Napoca

430031

Baia Mare

800578

Galati

7501126

Santiago

7510186

Santiago

00000

Santiago

H-8200

Veszprém

06700

Mexico City

Lima 1

Lima

Lima 25

Lima

Lima 27

Lima

San Isidro

Lima 34

Lima

Lima 41

Lima

L27 Lima

San Isidro

15-099

Bialystok

15-461

Bialystok

82-300

Elblag

64-000

Kościan

30-510

Krakow

20-607

Lublin

02-653

Warsaw

010584

Bucharest

011172

Bucharest

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY